概要
目的
探究腹腔肿瘤微环境内脂肪因子趋化素 (chemerin) 与程序性死亡配体-1 (PD-L1) 是否存在关联, 及其对卵巢癌细胞系 HO8910 细胞生物学功能的影响.
创新点
首次发现了 chemerin 可以上调卵巢癌细胞 PD-L1 的表达, 促进肿瘤增殖和迁移. 这对进一步研究免疫抑制剂在卵巢癌治疗中的应用、 卵巢癌的早期诊断, 以及血清和腹水中 chemerin 的检测具有一定的指导意义. 此外, chemerin 结合其他脂肪因子是否能成为卵巢癌诊断的标志物, 需进一步的研究证实.
方法
使用酶联免疫吸附剂测定 (ELISA) 检测卵巢癌患者腹水和血清中 chemerin 的含量; 使用免疫组化检测卵巢癌肿瘤组织中 chemerin 和 PD-L1 的表达; 使用免疫印迹法检测卵巢癌组织中 PD-L1 的表达及在 HO8910 和 HO891PM 细胞中 chemerin 表达的差异; 利用浓度分别为 0、 10、 50 和 100 ng/mL 外源性 chemerin 刺激 HO8910 和 HO8910PM 细胞; 使用水溶性四唑 (WST) 检测细胞增殖; 使用划痕实验检测细胞迁移功能; 利用鬼笔环肽荧光染色在共聚焦显微镜下观察 PD-L1 敲除前后的 HO8910 和 HO8910PM 的细胞骨架变化; 使用免疫印迹法检测细胞骨架蛋白的表达情况.
结论
Chemerin 可以上调卵巢癌细胞 PD-L1 的表达, 对肿瘤增殖和迁移具有促进作用.
This is a preview of subscription content, log in via an institution to check access.
References
Alkady MM, Abdel-Messeih PL, Nosseir NM, 2018. Assessment of serum levels of the adipocytokine chemerin in colorectal cancer patients. J Med Biochem, 37(3):313–319. https://doi.org/10.1515/jomb-2017-0062
Barbolina MV, 2018. Molecular mechanisms regulating organ-specific metastases in epithelial ovarian carcinoma. Cancers (Basel), 10(11):444. https://doi.org/10.3390/cancers10110444
Chang CH, Qiu J, O’Sullivan D, et al., 2015. Metabolic competition in the tumor microenvironment is a driver of cancer progression. Cell, 162(6):1229–1241. https://doi.org/10.1016/j.cell.2015.08.016
Chi JY, Wu ZH, Choi CHJ, et al., 2018. Three-dimensional adipose tissue imaging reveals regional variation in beige fat biogenesis and PRDM16-dependent sympathetic neurite density. Cell Metab, 27(1):226–236.e3. https://doi.org/10.1016/j.cmet.2017.12.011
Clark CA, Gupta HB, Sareddy G, et al., 2016. Tumor-intrinsic PD-L1 signals regulate cell growth, pathogenesis, and autophagy in ovarian cancer and melanoma. Cancer Res, 76(23):6964–6974. https://doi.org/10.1158/0008-5472.CAN-16-0258
Drakes ML, Stiff PJ, 2018. Regulation of ovarian cancer prognosis by immune cells in the tumor microenvironment. Cancers (Basel), 10(9):302. https://doi.org/10.3390/cancers10090302
El-Sagheer G, Gayyed M, Ahmad A, et al., 2018. Expression of chemerin correlates with a poor prognosis in female breast cancer patients. Breast Cancer (Dove Med Press), 10:169–176. https://doi.org/10.2147/BCTT.S178181
Freeman GJ, Long AJ, Iwai Y, et al., 2000. Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. J Exp Med, 192(7):1027–1034. https://doi.org/10.1084/jem.192.7.1027
Garcia-Diaz A, Shin DS, Moreno BH, et al., 2017. Interferon receptor signaling pathways regulating PD-L1 and PD-L2 expression. Cell Rep, 19(6):1189–1201. https://doi.org/10.1016/j.celrep.2017.04.031
Ghallab NA, Shaker OG, 2017. Serum and salivary levels of chemerin and MMP-9 in oral squamous cell carcinoma and oral premalignant lesions. Clin Oral Investig, 21(3): 937–947. https://doi.org/10.1007/s00784-016-1846-8
Ghebeh H, Mohammed S, Al-Omair A, et al., 2006. The B7-H1 (PD-L1) T lymphocyte-inhibitory molecule is expressed in breast cancer patients with infiltrating ductal carcinoma: correlation with important high-risk prognostic factors. Neoplasia, 8(3):190–198. https://doi.org/10.1593/neo.05733
Goralski KB, Jackson AE, McKeown BT, et al., 2019. More than an adipokine: the complex roles of chemerin signaling in cancer. Int J Mol Sci, 20(19):4778. https://doi.org/10.3390/ijms20194778
Hamanishi J, Mandai M, Iwasaki M, et al., 2007. Programmed cell death 1 ligand 1 and tumor-infiltrating CD8+ T lymphocytes are prognostic factors of human ovarian cancer. Proc Natl Acad Sci USA, 104(9):3360–3365. https://doi.org/10.1073/pnas.0611533104
Ho Y, Wang SH, Chen YR, et al., 2019. Leptin-derived peptides block leptin-induced proliferation by reducing expression of pro-inflammatory genes in hepatocellular carcinoma cells. Food Chem Toxicol, 133:110808. https://doi.org/10.1016/j.fct.2019.110808
Hoffmann M, Rak A, Ptak A, 2018. Bisphenol A and its derivatives decrease expression of chemerin, which reverses its stimulatory action in ovarian cancer cells. Toxicol Lett, 291:61–69. https://doi.org/10.1016/j.toxlet.2018.04.004
Ibrahim MM, 2010. Subcutaneous and visceral adipose tissue: structural and functional differences. Obes Rev, 11–18. https://doi.org/10.1111/j.1467-789X.2009.00623.x
Ishikawa M, Kitayama J, Nagawa H, 2004. Enhanced expression of leptin and leptin receptor (OB-R) in human breast cancer. Clin Cancer Res, 10(13):4325–4331. https://doi.org/10.1158/1078-0432.CCR-03-0749
Kumar JD, Kandola S, Tiszlavicz L, et al., 2016. The role of chemerin and ChemR23 in stimulating the invasion of squamous oesophageal cancer cells. Br J Cancer, 114(10): 1152–1159. https://doi.org/10.1038/bjc.2016.93
Kumar JD, Aolymat I, Tiszlavicz L, et al., 2019. Chemerin acts via CMKLR1 and GPR1 to stimulate migration and invasion of gastric cancer cells: putative role of decreased TIMP-1 and TIMP-2. Oncotarget, 10(2):98–112. https://doi.org/10.18632/oncotarget.26414
Li JJ, Yin HK, Guan DX, et al., 2018. Chemerin suppresses hepatocellular carcinoma metastasis through CMKLR1-PTEN-Akt axis. Br J Cancer, 118(10):1337–1348. https://doi.org/10.1038/s41416-018-0077-y
Maine CJ, Aziz NHA, Chatterjee J, et al., 2014. Programmed death ligand-1 over-expression correlates with malignancy and contributes to immune regulation in ovarian cancer. Cancer Immunol Immunother, 63(3):215–224. https://doi.org/10.1007/s00262-013-1503-x
Nieman KM, Kenny HA, Penicka CV, et al., 2011. Adipocytes promote ovarian cancer metastasis and provide energy for rapid tumor growth. Nat Med, 17(11):1498–1503. https://doi.org/10.1038/nm.2492
Pachynski RK, Zabel BA, Kohrt HE, et al., 2012. The chemoattractant chemerin suppresses melanoma by recruiting natural killer cell antitumor defenses. J Exp Med, 209(8): 1427–1435. https://doi.org/10.1084/jem.20112124
Paget S, 1889. The distribution of secondary growths in cancer of the breast. The Lancet, 133(3412):571–573. https://doi.org/10.1016/S0140-6736(00)49915-0
Reid BM, Permuth JB, Sellers TA, 2017. Epidemiology of ovarian cancer: a review. Cancer Biol Med, 14(1):9–32. https://doi.org/10.20892/j.issn.2095-3941.2016.0084
Rennier K, Shin WJ, Krug E, et al., 2020. Chemerin reactivates PTEN and suppresses PD-L1 in tumor cells via modulation of a novel CMKLR1-mediated signaling cascade. Clin Cancer Res, 26(18):5019–5035. https://doi.org/10.1158/1078-0432.CCR-19-4245
Reverchon M, Cornuau M, Rame C, et al., 2012. Chemerin inhibits IGF-1-induced progesterone and estradiol secretion in human granulosa cells. Hum Reprod, 27(6):1790–1800. https://doi.org/10.1093/humrep/des089
Shin WJ, Pachynski RK, 2018. Chemerin modulation of tumor growth: potential clinical applications in cancer. Discov Med, 26(141):31–37.
Steele CB, Thomas CC, Henley SJ, et al., 2017. Vital signs: trends in incidence of cancers associated with overweight and obesity—United States, 2005–2014. MMWR Morb Mortal Wkly Rep, 66(39):1052–1058. https://doi.org/10.15585/mmwr.mm6639e1
Treeck O, Buechler C, Ortmann O, 2019. Chemerin and cancer. Int J Mol Sci, 20(15):3750. https://doi.org/10.3390/ijms20153750
Wang CH, Wu WKK, Liu XD, et al., 2014. Increased serum chemerin level promotes cellular invasiveness in gastric cancer: a clinical and experimental study. Peptides, 51: 131–138. https://doi.org/10.1016/j.peptides.2013.10.009
Wang ZM, Aguilar EG, Luna JI, et al., 2019. Paradoxical effects of obesity on T cell function during tumor progression and PD-1 checkpoint blockade. Nat Med, 25(1):141–151. https://doi.org/10.1038/s41591-018-0221-5
Wise HM, Hermida MA, Leslie NR, 2017. Prostate cancer, PI3K, PTEN and prognosis. Clin Sci (Lond), 131(3):197–210. https://doi.org/10.1042/CS20160026
Zhang J, Jin HC, Zhu AK, et al., 2014. Prognostic significance of plasma chemerin levels in patients with gastric cancer. Peptides, 61:7–11. https://doi.org/10.1016/j.peptides.2014.08.007
Acknowledgments
This work was supported by the Special Project for Central Guidance of Local Science and Technology Development of Liaoning Province (No. 2019JH6/10400006), China.
Author information
Authors and Affiliations
Contributions
Chenxi GAO, Jinming SHI, and Jingxin ZHANG performed the experimental research and data analysis, and wrote the manuscript. Yin LI and Yi ZHANG contributed to the study design, data analysis, and writing and editing of the manuscript. All authors have read and approved the final manuscript, and therefore, have full access to all the data in the study and take responsibility for the integrity and security of the data.
Corresponding authors
Ethics declarations
Chenxi GAO, Jinming SHI, Jingxin ZHANG, Yin LI, and Yi ZHANG declare that they have no conflict of interest.
All procedures followed were in accordance with the ethical standards of the responsible committee on human experimentation (institutional and national) and with the Helsinki Declaration of 1975, as revised in 2008 (5). Informed consent was obtained from all patients for being included in the study. Additional informed consent was obtained from all patients for whom identifying information is included in this article.
Additional information
Materials and methods
Detailed methods are provided in the electronic supplementary materials of this paper.
Supplementary information
Materials and methods
Rights and permissions
About this article
Cite this article
Gao, C., Shi, J., Zhang, J. et al. Chemerin promotes proliferation and migration of ovarian cancer cells by upregulating expression of PD-L1. J. Zhejiang Univ. Sci. B 23, 164–170 (2022). https://doi.org/10.1631/jzus.B2100392
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1631/jzus.B2100392